Kunchok Dorjee1, Tsering Choden2, Sanjiv M Baxi3, Craig Steinmaus4, Arthur L Reingold4. 1. Division of Epidemiology, School of Public Health, University of California Berkeley, Berkeley, CA, USA; Center for Tuberculosis Research, School of Medicine, Johns Hopkins University, Baltimore, MD, USA. Electronic address: kunchok@berkeley.edu. 2. School of Public Health, Department of Epidemiology and Biostatistics, State University of New York Downstate Medical Center, Brooklyn, NY, USA. 3. Division of Epidemiology, School of Public Health, University of California Berkeley, Berkeley, CA, USA; Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, CA, USA. 4. Division of Epidemiology, School of Public Health, University of California Berkeley, Berkeley, CA, USA.
Abstract
OBJECTIVES: Abacavir's potential to cause cardiovascular disease (CVD) among people living with HIV (PLWH) is debated. We conduct a systematic review and meta-analyses to assess CVD risk from recent and cumulative abacavir exposure. METHODS: We searched Medline, Embase, Web of Science, abstracts from Conference on Retroviruses and Opportunistic Infections, and International AIDS Society/AIDS Conferences and bibliographies of review articles to identify research studies published through 2018 on CVD risk associated with abacavir exposure among PLWH. Studies assessing risk of CVD associated with recent (exposure within last 6 months) or cumulative abacavir exposure across all age-groups were eligible. Risks were quantified using fixed- and random-effects models. RESULTS: Of 378 unique citations, 68 full-text research articles and abstracts were reviewed. Seventeen studies assessed risk of CVD from recent or cumulative abacavir exposure. Summary relative risk (sRR) is increased for recent exposure (n=16 studies, sRR=1.61; 95% confidence interval: 1.48-1.75), higher in antiretroviral-therapy-naive population (n=5, 1.91; 1.48-2.46) and all studies reported RR>1. The sRR for recent exposure was similarly increased for the outcome of acute myocardial infarction, and for studies that adjusted for substance abuse, smoking, prior CVD, traditional CVD risk factors, and CD4 cell-count/HIV viral load. The sRR was increased for cumulative abacavir exposure (per year) (n=4, 1.12; 1.05-1.20) but no increase was seen after adjusting for recent exposure (n=5, 1.00; 0.93-1.08). CONCLUSIONS: Our findings suggest an increased risk of CVD from recent abacavir exposure. The risk remained elevated after adjusting for potential confounders. Further investigations are needed to understand CVD risk from cumulative exposure.
OBJECTIVES:Abacavir's potential to cause cardiovascular disease (CVD) among people living with HIV (PLWH) is debated. We conduct a systematic review and meta-analyses to assess CVD risk from recent and cumulative abacavir exposure. METHODS: We searched Medline, Embase, Web of Science, abstracts from Conference on Retroviruses and Opportunistic Infections, and International AIDS Society/AIDS Conferences and bibliographies of review articles to identify research studies published through 2018 on CVD risk associated with abacavir exposure among PLWH. Studies assessing risk of CVD associated with recent (exposure within last 6 months) or cumulative abacavir exposure across all age-groups were eligible. Risks were quantified using fixed- and random-effects models. RESULTS: Of 378 unique citations, 68 full-text research articles and abstracts were reviewed. Seventeen studies assessed risk of CVD from recent or cumulative abacavir exposure. Summary relative risk (sRR) is increased for recent exposure (n=16 studies, sRR=1.61; 95% confidence interval: 1.48-1.75), higher in antiretroviral-therapy-naive population (n=5, 1.91; 1.48-2.46) and all studies reported RR>1. The sRR for recent exposure was similarly increased for the outcome of acute myocardial infarction, and for studies that adjusted for substance abuse, smoking, prior CVD, traditional CVD risk factors, and CD4 cell-count/HIV viral load. The sRR was increased for cumulative abacavir exposure (per year) (n=4, 1.12; 1.05-1.20) but no increase was seen after adjusting for recent exposure (n=5, 1.00; 0.93-1.08). CONCLUSIONS: Our findings suggest an increased risk of CVD from recent abacavir exposure. The risk remained elevated after adjusting for potential confounders. Further investigations are needed to understand CVD risk from cumulative exposure.
Authors: Andy I Choi; Eric Vittinghoff; Steven G Deeks; Cristin C Weekley; Yongmei Li; Michael G Shlipak Journal: AIDS Date: 2011-06-19 Impact factor: 4.177
Authors: Claudette S Satchell; Jane A O'Halloran; Aoife G Cotter; Aaron J Peace; Eileen F O'Connor; Anthony F Tedesco; Eoin R Feeney; John S Lambert; Gerard J Sheehan; Dermot Kenny; Patrick W G Mallon Journal: J Infect Dis Date: 2011-10-15 Impact factor: 5.226
Authors: Daniel Podzamczer; Elena Ferrer; Pochita Sanchez; José M Gatell; Manel Crespo; Cesar Fisac; Montse Lonca; Jose Sanz; Jordi Niubo; Sergio Veloso; Josep M Llibre; Pilar Barrufet; María A Ribas; Esperanza Merino; Esteban Ribera; Javier Martínez-Lacasa; Carlos Alonso; Miquel Aranda; Federico Pulido; Juan Berenguer; Antonio Delegido; Juan D Pedreira; Ana Lérida; Rafael Rubio; Luis del Río Journal: J Acquir Immune Defic Syndr Date: 2007-02-01 Impact factor: 3.731
Authors: Priscilla Y Hsue; Peter W Hunt; Yuaner Wu; Amanda Schnell; Jennifer E Ho; Hiroyu Hatano; Yu Xie; Jeffrey N Martin; Peter Ganz; Steven G Deeks Journal: AIDS Date: 2009-09-24 Impact factor: 4.177
Authors: Caroline A Sabin; Signe W Worm; Rainer Weber; Peter Reiss; Wafaa El-Sadr; Francois Dabis; Stephane De Wit; Matthew Law; Antonella D'Arminio Monforte; Nina Friis-Møller; Ole Kirk; Christian Pradier; Ian Weller; Andrew N Phillips; Jens D Lundgren Journal: Lancet Date: 2008-04-02 Impact factor: 202.731
Authors: Suman Srinivasa; Janet Lo; Milana Bogorodskaya; Kathleen V Fitch; Michael Lu; Martin Torriani; Markella V Zanni; Sara E Looby; Sanjna Iyengar; Virginia A Triant; Steven K Grinspoon Journal: Obesity (Silver Spring) Date: 2020-02-21 Impact factor: 5.002
Authors: Z C Lim; G S Hoo; J H Ang; C B Teng; L W Ang; C C Lee; Y S Leo; H L Law; O T Ng; C S Wong Journal: AIDS Res Ther Date: 2021-11-01 Impact factor: 2.250
Authors: Anca Streinu-Cercel; Oana Săndulescu; Cătălina Poiană; Maria Dorobanţu; Gabriel Mircescu; Voichiţa Elena Lăzureanu; Irina-Magdalena Dumitru; Odette Chirilă; Adrian Streinu-Cercel Journal: Germs Date: 2019-12-02
Authors: Claudia A Martinez; Rishi Rikhi; Mollie S Pester; Meela Parker; Alex Gonzalez; Michaela Larson; Jennifer Chavez; Armando Mendez; Jeffrey K Raines; Michael A Kolber; Ivonne H Schulman; Maria L Alcaide; Barry E Hurwitz Journal: PLoS One Date: 2022-03-10 Impact factor: 3.240